Skip to content

Optimal Brain Oxygenation in Neurologic Intensive Care Unit : The NeurO2 Study

Anemia | Traumatic Brain Injury | Subarachnoid Hemorrhage | Brain Injuries | Intensive Care Neurological...

The NeurO2 study is a multicenter observational study looking at NIRS monitoring in neurocrocritically ill patients during the acute phase of care following an acute brain injury. The study is nested within the HEMOTION Trial and the SAHaRA Trial

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion criteria:

* Enrolment in one of the parent trials (HEMOTION or SAHaRA trials)
* HEMOTION trial (acute moderate of severe blunt traumatic brain injury (Glasgow Coma Score18 \[GCS\] ≤ 12))
* SAHaRA trial (acute subarachnoid hemorrhage as confirmed by treating neurosurgeon or neuro-interventionist and supported by blood in subarachnoid space resulting from a ruptured aneurysm)
* Adult patients (age ≥18 years old)
* Patients suffering from anemia (Hb ≤100 g/L)

Exclusion criteria:

* Contraindications or known objections to blood transfusions
* Active bleeding with hemodynamic instability at the time of enrollment
* Decision to withdraw or withhold life-sustaining therapies made
* NIRS monitoring not reliable

Study Location

CHU de Québec - Université Laval (Hôpital de l'Enfant-Jésus)
CHU de Québec - Université Laval (Hôpital de l'Enfant-Jésus)
Québec City, Quebec
Canada

Contact Study Team

Primary Contact

Alexis Turgeon, MD MSc

[email protected]
418-525-4444
The Ottawa Hospital
The Ottawa Hospital
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Shane W English, MD MSc

Study Sponsored By
CHU de Quebec-Universite Laval
Participants Required
More Information
Study ID: NCT04935866